Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02199574 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT02199574 is a Phase 4 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT02199574, a Phase 4 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the pharmacokinetic (PK) profile of a single dose of EXPAREL (133 mg/10 mL) administered intraoperatively per normal infiltration for prolonged analgesia in 12 adult subjects undergoing tonsillectomy with or without removal of the adenoids.
Interventions
- DRUG EXPAREL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02199574
The ClinicalTrials.gov registry entry for NCT02199574 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EXPAREL is the first listed.
NCT02199574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02199574 about?
NCT02199574 is a clinical study titled "Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy". The purpose of this study is to characterize the pharmacokinetic (PK) profile of a single dose of EXPAREL (133 mg/10 mL) administered intraoperatively per normal infiltration for prolonged analgesia in 12 adult subjects undergoing tonsillectomy with or without removal of the adenoids.
What is the current status of trial NCT02199574?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2014-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02199574?
The interventions under investigation include: EXPAREL (DRUG).
Who is sponsoring clinical trial NCT02199574?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.